<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35966512</PMID><DateRevised><Year>2022</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2297-055X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in cardiovascular medicine</Title><ISOAbbreviation>Front Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors.</ArticleTitle><Pagination><StartPage>916156</StartPage><MedlinePgn>916156</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">916156</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcvm.2022.916156</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Cardiovascular events are common in COVID-19. While the use of anticoagulation during hospitalization has been established in current guidelines, recommendations regarding antithrombotic therapy in the post-discharge period are conflicting.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">To investigate this issue, we conducted a retrospective follow-up (393 &#xb1; 87 days) of 1,746 consecutive patients, hospitalized with and surviving COVID-19 pneumonia at a single tertiary medical center between April and December 2020. Survivors received either 30-day post-discharge antithrombotic treatment regime using prophylactic direct oral anticoagulation (DOAC; <i>n</i> = 1,002) or dipyridamole (<i>n</i> = 304), or, no post-discharge antithrombotic treatment (Ctrl; <i>n</i> = 440). All-cause mortality, as well as cardiovascular mortality (CVM) and further cardiovascular outcomes (CVO) resulting in hospitalization due to pulmonary embolism (PE), myocardial infarction (MI) and stroke were investigated during the follow-up period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">While no major bleeding events occured during follow-up in the treatment groups, Ctrl showed a high but evenly distributed rate all-cause mortality. All-cause mortality (CVM) was attenuated by prophylactic DOAC (0.6%, <i>P</i> &lt; 0.001) and dipyridamole (0.7%, <i>P</i> &lt; 0.001). This effect was also evident for both therapies after propensity score analyses using weighted binary logistic regression [DOAC: <i>B</i> = -3.33 (0.60), <i>P</i> &lt; 0.001 and dipyridamole: <i>B</i> = -3.04 (0.76), <i>P</i> &lt; 0.001]. While both treatment groups displayed a reduced rate of CVM [DOAC: <i>B</i> = -2.69 (0.74), <i>P</i> &lt; 0.001 and dipyridamole: <i>B</i> = -17.95 (0.37), <i>P</i> &lt; 0.001], the effect in the DOAC group was driven by reduction of both PE [<i>B</i>-3.12 (1.42), <i>P</i> = 0.012] and stroke [<i>B</i> = -3.08 (1.23), <i>P</i> = 0.028]. Dipyridamole significantly reduced rates of PE alone [<i>B</i> = -17.05 (1.01), <i>P</i> &lt; 0.001].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Late cardiovascular events and all-cause mortality were high in the year following hospitalization for COVID-19. Application of prophylactic DOAC or dipyridamole in the early post-discharge period improved mid- and long-term CVO and all-cause mortality in COVID-19 survivors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Motloch, Jirak, Mirna, Fiedler, Davtyan, Lakman, Gareeva, Tyurin, Gumerov, Matskeplishvili, Pavlov, Cai, Kopp, Topf, Hoppe, Pistulli and Zagidullin.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Motloch</LastName><ForeName>Lukas J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Clinic II for Internal Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jirak</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinic II for Internal Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirna</LastName><ForeName>Moritz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinic II for Internal Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiedler</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinic II for Internal Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Cardiology, Nephrology and Intensive Care Medicine, Hospital Wiener Neustadt, Wiener Neustadt, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davtyan</LastName><ForeName>Paruir A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakman</LastName><ForeName>Irina A</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scientific Laboratory for the Study of Socio-Economic Problems of the Regions Bashkir State University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gareeva</LastName><ForeName>Diana F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tyurin</LastName><ForeName>Anton V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Department of Internal Diseases II, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gumerov</LastName><ForeName>Ruslan M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matskeplishvili</LastName><ForeName>Simon T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Lomonosov Moscow State University Medical Center, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavlov</LastName><ForeName>Valentin N</ForeName><Initials>VN</Initials><AffiliationInfo><Affiliation>Department of Urology, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Benzhi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kopp</LastName><ForeName>Kristen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinic II for Internal Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topf</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinic II for Internal Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoppe</LastName><ForeName>Uta C</ForeName><Initials>UC</Initials><AffiliationInfo><Affiliation>Clinic II for Internal Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistulli</LastName><ForeName>Rudin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Munster, Munster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zagidullin</LastName><ForeName>Naufal S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cardiovasc Med</MedlineTA><NlmUniqueID>101653388</NlmUniqueID><ISSNLinking>2297-055X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cardiovascular disease in COVID-19</Keyword><Keyword MajorTopicYN="N">dipyridamole</Keyword><Keyword MajorTopicYN="N">direct anticoagulation</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>15</Day><Hour>3</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35966512</ArticleId><ArticleId IdType="pmc">PMC9372296</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2022.916156</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. (2020) 135:2033&#x2013;40. 10.1182/blood.2020006000</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020006000</ArticleId><ArticleId IdType="pmc">PMC7273827</ArticleId><ArticleId IdType="pubmed">32339221</ArticleId></ArticleIdList></Reference><Reference><Citation>Godeau D, Petit A, Richard I, Roquelaure Y, Descatha A. Return-to-work, disabilities and occupational health in the age of COVID-19: Scand. J Work Environ Health. (2021) 47:408&#x2013;9. 10.5271/sjweh.3960</Citation><ArticleIdList><ArticleId IdType="doi">10.5271/sjweh.3960</ArticleId><ArticleId IdType="pmc">PMC8259700</ArticleId><ArticleId IdType="pubmed">34003294</ArticleId></ArticleIdList></Reference><Reference><Citation>Godino C, Scotti A, Maugeri N, Mancini N, Fominskiy E, Margonato A, et al. . Antithrombotic therapy in patients with COVID-19? -Rationale and evidence. Int J Cardiol. (2021) 324:261&#x2013;6. 10.1016/j.ijcard.2020.09.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2020.09.064</ArticleId><ArticleId IdType="pmc">PMC7521414</ArticleId><ArticleId IdType="pubmed">33002521</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc Disord. (2015) 15:015&#x2013;24. 10.1186/s12872-015-0124-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-015-0124-z</ArticleId><ArticleId IdType="pmc">PMC4617895</ArticleId><ArticleId IdType="pubmed">26481314</ArticleId></ArticleIdList></Reference><Reference><Citation>Manolis AS, Manolis TA, Manolis AA, Papatheou D, Melita H. COVID-19 infection: viral macro- and micro-vascular coagulopathy and thromboembolism/prophylactic and therapeutic management. J Cardiovasc Pharmacol Ther. (2021) 26:12&#x2013;24. 10.1177/1074248420958973</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1074248420958973</ArticleId><ArticleId IdType="pmc">PMC7492826</ArticleId><ArticleId IdType="pubmed">32924567</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashidi F, Barco S, Kamangar F, Heresi GA, Emadi A, Kaymaz C, et al. . Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: prospective results from a multi-center study. Thromb Res. (2021) 198:135&#x2013;8. 10.1016/j.thromres.2020.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.12.001</ArticleId><ArticleId IdType="pmc">PMC7836837</ArticleId><ArticleId IdType="pubmed">33338976</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannis D, Allen SL, Tsang J, Flint S, Pinhasov T, Williams S, et al. . Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood. (2021) 137:2838&#x2013;47. 10.1182/blood.2020010529</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020010529</ArticleId><ArticleId IdType="pmc">PMC8032474</ArticleId><ArticleId IdType="pubmed">33824972</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, et al. . Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the inspiration randomized clinical trial. JAMA. (2021) 325:1620&#x2013;30. 10.1001/jama.2021.4152</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.4152</ArticleId><ArticleId IdType="pmc">PMC7974835</ArticleId><ArticleId IdType="pubmed">33734299</ArticleId></ArticleIdList></Reference><Reference><Citation>Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, et al. . Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N Engl J Med. (2021) 385:777&#x2013;89. 10.1056/NEJMoa2103417</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2103417</ArticleId><ArticleId IdType="pmc">PMC8362592</ArticleId><ArticleId IdType="pubmed">34351722</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, et al. . Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N Engl J Med. (2021) 385:790&#x2013;802. 10.1056/NEJMoa2105911</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105911</ArticleId><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ten Cate H. Surviving COVID-19 with Heparin? N Engl J Med. (2021) 385:845&#x2013;6. 10.1056/NEJMe2111151</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe2111151</ArticleId><ArticleId IdType="pmc">PMC8362589</ArticleId><ArticleId IdType="pubmed">34347948</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo V, Bottino R, D'Andrea A, Silverio A, Di Maio M, Golino P, et al. . Chronic oral anticoagulation and clinical outcome in Hospitalized COVID-19 patients [Published Online Ahead of print, 2021 May 14]. Cardiovasc Drugs Ther. (2021) 1&#x2013;8. 10.1007/s10557-021-07194-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-021-07194-y</ArticleId><ArticleId IdType="pmc">PMC8120255</ArticleId><ArticleId IdType="pubmed">33988835</ArticleId></ArticleIdList></Reference><Reference><Citation>Jirak P, Larbig R, Shomanova Z, Frob EJ, Dankl D, Torgersen C, et al. . Myocardial injury in severe COVID-19 is similar to pneumonias of other origin: results from a multicentre study. ESC Heart Fail. (2021) 8:37&#x2013;46. 10.1002/ehf2.13136</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13136</ArticleId><ArticleId IdType="pmc">PMC7835505</ArticleId><ArticleId IdType="pubmed">33350605</ArticleId></ArticleIdList></Reference><Reference><Citation>Paar V, Wernly B, Zhou Z, Motloch LJ, Hoppe UC, Egle A, et al. . Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory? J Thromb Thrombolysis. (2021) 51:226&#x2013;31. 10.1007/s11239-020-02212-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02212-6</ArticleId><ArticleId IdType="pmc">PMC7338133</ArticleId><ArticleId IdType="pubmed">32632558</ArticleId></ArticleIdList></Reference><Reference><Citation>Smilowitz NR, Nguy V, Aphinyanaphongs Y, Newman JD, Xia Y, Reynolds HR, et al. . Multiple biomarker approach to risk stratification in COVID-19. Circulation. (2021) 143:1338&#x2013;40. 10.1161/CIRCULATIONAHA.120.053311</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.053311</ArticleId><ArticleId IdType="pmc">PMC7996053</ArticleId><ArticleId IdType="pubmed">33587646</ArticleId></ArticleIdList></Reference><Reference><Citation>Mengozzi A, Georgiopoulos G, Falcone M, Tiseo G, Pugliese NR, Dimopoulos MA, et al. . The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcome. Sci Rep. (2021) 11:021&#x2013;85646. 10.1038/s41598-021-85646-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-85646-z</ArticleId><ArticleId IdType="pmc">PMC7985490</ArticleId><ArticleId IdType="pubmed">33753759</ArticleId></ArticleIdList></Reference><Reference><Citation>Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, et al. . Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. Am J Hematol. (2021) 96:471&#x2013;9. 10.1002/ajh.26102</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26102</ArticleId><ArticleId IdType="pmc">PMC8013588</ArticleId><ArticleId IdType="pubmed">33476420</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger JS, Kornblith LZ, Gong MN, Reynolds HR, Cushman M, Cheng Y, et al. . Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial. JAMA. (2022) 327:227&#x2013;36. 10.1001/jama.2021.23605</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.23605</ArticleId><ArticleId IdType="pmc">PMC8767444</ArticleId><ArticleId IdType="pubmed">35040887</ArticleId></ArticleIdList></Reference><Reference><Citation>Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. . Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. (2022) 399:143&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8598213</ArticleId><ArticleId IdType="pubmed">34800427</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzaroni MG, Piantoni S, Masneri S, Garrafa E, Martini G, Tincani A, et al. . Coagulation dysfunction in COVID-19: the interplay between inflammation, viral infection and the coagulation system. Blood Rev. (2021) 46:24. 10.1016/j.blre.2020.100745</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2020.100745</ArticleId><ArticleId IdType="pmc">PMC7444609</ArticleId><ArticleId IdType="pubmed">32868115</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Li Z, Liu S, Sun J, Chen Z, Jiang M, et al. . Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm Sin B. (2020) 10:1205&#x2013;15. 10.1016/j.apsb.2020.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2020.04.008</ArticleId><ArticleId IdType="pmc">PMC7169892</ArticleId><ArticleId IdType="pubmed">32318327</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. (2022) 7:022&#x2013;01689. 10.1038/s41591-022-01689-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. . Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. Chest. (2020) 158:1143&#x2013;63. 10.1016/j.chest.2020.05.559</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.05.559</ArticleId><ArticleId IdType="pmc">PMC7265858</ArticleId><ArticleId IdType="pubmed">32502594</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al. . Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. (2020) 18:1859&#x2013;65. 10.1111/jth.14929</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14929</ArticleId><ArticleId IdType="pmc">PMC7283841</ArticleId><ArticleId IdType="pubmed">32459046</ArticleId></ArticleIdList></Reference><Reference><Citation>Federation MoHotR . Version 8 of the temporal recommendations for the prevention, diagnosis and treatment of the novel coronavirus infection COVID-19 by Russian Ministry of Healthcare. Available online at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVID-19_v8.pdf</Citation></Reference><Reference><Citation>Ramacciotti E, Barile Agati L, Calderaro D, Aguiar VCR, Spyropoulos AC, de Oliveira CCC, et al. . Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. (2022) 399:50&#x2013;9. 10.1016/S0140-6736(21)02392-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02392-8</ArticleId><ArticleId IdType="pmc">PMC8673881</ArticleId><ArticleId IdType="pubmed">34921756</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Management of COVID-19: Interim Guidance . Available online at: WHO/2019-nCoV/clinical/2021.2 (accessed May 27, 2020).</Citation></Reference><Reference><Citation>Priori SG, Blomstr&#xf6;m-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. . 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC). endorsed by: association for European paediatric and congenital cardiology (AEPC). Eur Heart J. (2015) 36:2793&#x2013;867. 10.1093/eurheartj/ehv316</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv316</ArticleId><ArticleId IdType="pubmed">26320108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. (2015) 13:2119&#x2013;26. 10.1111/jth.13140</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13140</ArticleId><ArticleId IdType="pubmed">26764429</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. (2013) 32:3388&#x2013;414. 10.1002/sim.5753</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5753</ArticleId><ArticleId IdType="pmc">PMC3710547</ArticleId><ArticleId IdType="pubmed">23508673</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts LN, Whyte MB, Georgiou L, Giron G, Czuprynska J, Rea C, et al. . Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood. (2020) 136:1347&#x2013;50. 10.1182/blood.2020008086</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008086</ArticleId><ArticleId IdType="pmc">PMC7483432</ArticleId><ArticleId IdType="pubmed">32746455</ArticleId></ArticleIdList></Reference><Reference><Citation>Eswaran H, Jarmul JA, Shaheen AW, Meaux D, Long T, Saccoccio D, et al. . Vascular thromboembolic events following COVID-19 hospital discharge: incidence and risk factors. Res Pract Thromb Haemost. (2021) 5:292&#x2013;5. 10.1002/rth2.12485</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12485</ArticleId><ArticleId IdType="pmc">PMC7938613</ArticleId><ArticleId IdType="pubmed">33733027</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox SE, Li G, Akmatbekov A, Harbert JL, Lameira FS, Brown JQ, et al. . Unexpected features of cardiac pathology in COVID-19 infection. Circulation. (2020) 142:1123&#x2013;5. 10.1161/CIRCULATIONAHA.120.049465</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.049465</ArticleId><ArticleId IdType="pubmed">32689809</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Xiao J, Sun R, Tang X, Liang C, Lin H, et al. . Prolonged persistence of SARS-CoV-2 RNA in body fluids. Emerg Infect Dis. (2020) 26:1834&#x2013;8. 10.3201/eid2608.201097</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2608.201097</ArticleId><ArticleId IdType="pmc">PMC7392422</ArticleId><ArticleId IdType="pubmed">32383638</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. . Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): A prospective cohort study. Clin Infect Dis. (2022) 74:1191&#x2013;98. 10.1093/cid/ciab611</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Balakumar P, Nyo YH, Renushia R, Raaginey D, Oh AN, Varatharajan R, et al. . Classical and pleiotropic actions of dipyridamole: not enough light to illuminate the dark tunnel? Pharmacol Res. (2014) 87:144&#x2013;50. 10.1016/j.phrs.2014.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2014.05.008</ArticleId><ArticleId IdType="pubmed">24861566</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. . &#x2018;Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. (2021) 76:396&#x2013;8. 10.1136/thoraxjnl-2020-215818</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackam DG, Spence JD. Antiplatelet therapy in ischemic stroke and transient ischemic attack. Stroke. (2019) 50:773&#x2013;8. 10.1161/STROKEAHA.118.023954</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.118.023954</ArticleId><ArticleId IdType="pubmed">30626286</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. . COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. (2020) 75:2950&#x2013;73. 10.1016/j.jacc.2020.04.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.031</ArticleId><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksu K, Donmez A, Keser G. Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des. (2012) 18:1478&#x2013;93. 10.2174/138161212799504731</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161212799504731</ArticleId><ArticleId IdType="pubmed">22364132</ArticleId></ArticleIdList></Reference><Reference><Citation>Naming tracking SARS-CoV-2 variants of concern variants of interest. 
WHO Tracking SARS-CoV-2 variants. WHO. (2021). Available online at: https://www.who.int/activities/tracking-SARS-CoV-2-variants</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>